GLUE vs. ATAI
GLUE (Monte Rosa Therapeutics, Inc.) and ATAI (Atai Life Sciences N.V.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, GLUE returned -0.45%/yr vs -25.61%/yr for ATAI. At a 0.37 correlation, their price movements are largely independent.
Performance
GLUE vs. ATAI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GLUE achieves a 32.08% return, which is significantly higher than ATAI's 0.24% return.
GLUE
- 1D
- 10.93%
- 1M
- 10.10%
- YTD
- 32.08%
- 6M
- 25.67%
- 1Y
- 346.34%
- 3Y*
- 44.95%
- 5Y*
- -0.45%
- 10Y*
- —
ATAI
- 1D
- 1.23%
- 1M
- -5.09%
- YTD
- 0.24%
- 6M
- -5.31%
- 1Y
- 102.97%
- 3Y*
- 38.30%
- 5Y*
- -25.61%
- 10Y*
- —
GLUE vs. ATAI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
GLUE Monte Rosa Therapeutics, Inc. | 32.08% | 125.94% | 22.83% | -25.76% | -62.73% | -7.18% |
ATAI Atai Life Sciences N.V. | 0.24% | 207.52% | -5.67% | -46.99% | -65.14% | -58.49% |
Correlation
The correlation between GLUE and ATAI is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.27 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.36 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.37 |
Correlation (All Time) Calculated using the full available price history since Jun 24, 2021 | 0.37 |
Fundamentals
GLUE:
-$2.26
ATAI:
-$2.67
GLUE:
27.74
ATAI:
292.00
GLUE:
$42.95M
ATAI:
$3.49M
GLUE:
$34.56M
ATAI:
$3.49M
GLUE:
-$139.25M
ATAI:
-$663.38M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GLUE vs. ATAI — Risk / Return Rank
GLUE
ATAI
GLUE vs. ATAI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Monte Rosa Therapeutics, Inc. (GLUE) and Atai Life Sciences N.V. (ATAI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GLUE | ATAI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.43 | ||
| Sortino ratioReturn per unit of downside risk | +2.39 | ||
| Omega ratioGain probability vs. loss probability | 1.53 | 1.27 | +0.26 |
| Calmar ratioReturn relative to maximum drawdown | 8.34 | 2.15 | +6.19 |
| Martin ratioReturn relative to average drawdown | 17.34 | 3.38 | +13.96 |
Loading charts...
Drawdowns
GLUE vs. ATAI - Drawdown Comparison
The maximum GLUE drawdown since its inception was -94.08%, roughly equal to the maximum ATAI drawdown of -95.05%. Use the drawdown chart below to compare losses from any high point for GLUE and ATAI.
Loading charts...
Drawdown Indicators
| GLUE | ATAI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.08% | -95.05% | +0.97% |
Max Drawdown (1Y)Largest decline over 1 year | -41.84% | -48.06% | +6.22% |
Max Drawdown (3Y)Largest decline over 3 years | -65.37% | -59.23% | -6.14% |
Max Drawdown (5Y)Largest decline over 5 years | -94.08% | -94.66% | +0.58% |
Current DrawdownCurrent decline from peak | -50.94% | -80.48% | +29.54% |
Average DrawdownAverage peak-to-trough decline | -74.39% | -80.78% | +6.39% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.09% | 30.58% | -10.49% |
Volatility
GLUE vs. ATAI - Volatility Comparison
Monte Rosa Therapeutics, Inc. (GLUE) and Atai Life Sciences N.V. (ATAI) have volatilities of 19.17% and 19.36%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GLUE | ATAI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.17% | 19.36% | -0.19% |
Volatility (6M)Calculated over the trailing 6-month period | 55.34% | 50.22% | +5.12% |
Volatility (1Y)Calculated over the trailing 1-year period | 93.10% | 80.92% | +12.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 101.00% | 83.61% | +17.39% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 101.00% | 83.59% | +17.41% |
Dividends
GLUE vs. ATAI - Dividend Comparison
Neither GLUE nor ATAI has paid dividends to shareholders.
Financials
GLUE vs. ATAI - Financials Comparison
This section allows you to compare key financial metrics between Monte Rosa Therapeutics, Inc. and Atai Life Sciences N.V.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
GLUE and ATAI have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ATAI has higher volatility (19.36%) compared to GLUE (19.17%). In terms of maximum drawdown, GLUE dropped -94.08% vs ATAI's -95.05%.
GLUE currently has the higher Sharpe Ratio (3.75 vs 1.32), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GLUE and ATAI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer